Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEC-176Cat.No.:HY-112906CASNo.:314054-00-7分?式:C??H?IN?O?分?量:358.09作?靶點:STING作?通路:Immunology/Inflammation儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:62.5mg/mL(174.54mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM2.7926mL13.9630mL27.9259mL5mM0.5585mL2.7926mL5.5852mL10mM0.2793mL1.3963mL2.7926mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。BIOLOGICALACTIVITY?物活性C-176?擾素因刺激受體(STING)的強效共價抑制劑。IC50&TargetSTING[1].體外研究C-176stronglyreducesSTING-mediated,butnotRIG-I-orTBK1-mediated,IFNβreporteractivity.1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEPretreatmentwithC-176markedlyreducetheCMA-mediatedinductionofserumlevelsoftypeIIFNsandIL-6[1].體內(nèi)研究C-176(750/375nmolC-176permousein200μLcornoil)significantlyreducestheCMA-mediatedinductionofserumlevelsoftypeIIFNsandIL-6.,withoutsignificanttoxicity[1].C-176resultsinasignificantreductioninserumlevelsoftypeIIFNsandinastrongsuppressionofinflammatoryparametersintheheart,withnoevidentsignsofoverttoxicityTrex1?/?mice[1].C-176demonstratesmarkedameliorationofvarioussignsofsystemicinflammationinTrex1?/?mice[1].AnimalModel:WTtypemice.Dosage:750/375nmolC-176permousein200μLcornoil(~1.34/0.67mg/mL).Administration:Intraperitoneally,once.Result:SignificantlyreducedSerumlevelsoftypeIIFNsandIL-6.戶使?本產(chǎn)品發(fā)表的科研?獻?JClinInvest.2021Oct15;131(20):e136329.?Neuron.2022Nov4;S0896-6273(22)00961-8.?AdvSci(Weinh).2021Jan6;8(5):2002738.?CancerRes.2021Apr5;canres.3738.2020.?CancerRes.2021Feb15;canres.2370.2020.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].HaagSM,etal.TargetingSTINGwithcovalentsmall-moleculeinhibitors.Nature.2018Jul;559(7713):269-273.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Te